PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10534697-2	1999	The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro.	tanespimycin	96-134	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	87-91	
10534697-5	1999	RESULTS: The 17-allylamino 17-demethoxygeldanamycin treatment efficiently depleted p185 expression in lung cancer cells.	tanespimycin	13-51	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	83-87	
10534697-6	1999	Concurrent exposure of these cells to paclitaxel and 17-allylamino 17-demethoxygeldanamycin significantly enhanced paclitaxel-mediated cytotoxicity, particularly in cells which overexpressed p185.	tanespimycin	53-91	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	191-195	
10534697-11	1999	CONCLUSION: The compound 17-allylamino 17-demethoxygeldanamycin sensitizes non-small cell lung cancer cells expressing high levels of p185 to paclitaxel-mediated growth arrest and apoptosis.	tanespimycin	25-63	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	134-138	
10534697-12	1999	These preclinical data support the evaluation of the combination of paclitaxel and 17-allylamino 17-demethoxygeldanamycin in the treatment of patients with lung cancer whose tumors exhibit p185 overexpression.	tanespimycin	83-121	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	189-193	
7562911-5	1995	Specifically, dosed intraperitoneally at 100 mg/kg, 17-(allylamino)-17-demethoxygeldanamycin and other 17-amino analogs were effective at reducing p185 phosphotyrosine in subcutaneous flank FRE/erbB-2 tumors.	tanespimycin	52-92	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	147-151